Ribo Announces Phase 2 Clinical Trial Submission to EMA, Further Advancing siRNA Therapeutics in Thromboembolic Disease
SUZHOU, China and MÖLNDAL, Sweden, May 28, 2026 /PRNewswire/ — Suzhou Ribo Life Science (stock code 06938.HK) and Ribocure Pharmaceuticals (together “Ribo”) announce the submission of Phase 2 Clinical Trial Application (CTA)
